Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY).

Full DD Report for CLVLY

Recent News from (OTC: CLVLY)

CLINUVEL unveils new global positioning
MELBOURNE, Australia, Feb. 19, 2018 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA-DAX:UR9) (NASDAQ INTERNATIONAL DESIGNATION ADR:CLVLY) today released its new global Company positioning including the unveiling of a new Group identity and website. The global identity refl...
Source: GlobeNewswire
Date: February, 19 2018 22:47
Clinuvel: Turtle Or Race Horse? Both Have Their Qualities
Clinuvel Pharmaceuticals ( CLVLY ) held their annual general shareholder meeting on November 28th, 2017, publishing updates on product and application roadmaps ( Presentation slides ). Being blunt, the company disappointed many shareholders by a very ordinary presentation, as they had raised...
Source: SeekingAlpha
Date: December, 01 2017 11:23
Clinuvel: High Cash Returns - Catalysts For Growth Lined Up
It has been almost 10 months ago that I wrote my first article on Clinuvel (CLVLY) on Seeking Alpha, explaining my investment case and valuation approach. My fair value target in January 2017 was 21-28 USD/share (upside of 240-350%), supported by a discounted cash flow model. Back then, the ...
Source: SeekingAlpha
Date: November, 10 2017 17:11
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
MELBOURNE, Australia and LEATHERHEAD, United Kingdom, April 12, 2017 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA:UR9) (OTC:CLVLY) today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband ...
Source: GlobeNewswire
Date: April, 12 2017 05:10
Clinuvel: Laying The Frist Brick For A Fortress Of Commercial Success
Some long-term investors already had lost their faith, but it finally happened: The Australian pharma/biotech company Clinuvel Pharmaceuticals (CLVLY) Pharmaceuticals, first struggling for many years with finding its market positioning, then struggling with the logic of the administrative auth...
Source: SeekingAlpha
Date: January, 19 2017 12:07
Clinuvel to file new drug with FDA
MELBOURNE, Australia and NEW YORK, July 18, 2016 (GLOBE NEWSWIRE) -- Clinuvel Pharmaceuticals (ASX:CUV) (OTC:CLVLY) (XETRA:UR9) today announced that the US Food and Drug Administration (FDA) has concluded an initial review of data from the use of its drug SCENESSE® (afamelanotide 16mg)...
Source: GlobeNewswire
Date: July, 18 2016 08:11
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPP NDA filing allowed on a rolling basis FDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment MELBOURNE, Australia and NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- ...
Source: GlobeNewswire
Date: July, 06 2016 08:02
Nasdaq Welcomes Additional Companies to the Nasdaq International Designation
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) today announced that Nidec Corporation (OTC:NJDCY) (TYO:6594) and Clinuvel Pharmaceuticals Ltd. (OTC:CLVLY) (ASX:CUV) have joined the Nasdaq International Designation program. Through their membership, Nidec an...
Source: GlobeNewswire
Date: June, 01 2016 15:50


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY)

Logo for Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY)

Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With our unique expertise in understanding the interaction of light and human skin, we have identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from , to million.


Contact Information



Current Management

  • Philippe Wolgen / CEO
  • Darren Keamy / CFO
  • Colin Mackie / Director, Bus. Dev.
  • Philippe Wolgen /

Current Share Structure

  • Market Cap: $212,671,970 - 03/15/2018
  • Issue and Outstanding: 30,381,710 - 12/31/2010


Daily Technical Chart for (OTC: CLVLY)

Daily Technical Chart for (OTC: CLVLY)

Stay tuned for daily updates and more on (OTC: CLVLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CLVLY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLVLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CLVLY and does not buy, sell, or trade any shares of CLVLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer:



Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us